论文部分内容阅读
目的探讨中国人群还原叶酸载体基因RFC1 G80A基因多态性与大剂量甲氨蝶呤化疗药物不良反应的关系。方法检索中国人群RFC1 G80A基因多态性与大剂量甲氨蝶呤药物不良反应相关性的研究,对符合标准的临床研究进行资料提取,运用Stata12.0统计软件进行Meta分析,比较不同RFC1 G80A基因型(AA vs GG+GA)患者的药物不良反应发生情况。结果共纳入8篇文献。Meta分析显示:中国人群RFC1 G80A AA型肝功能损伤、肾功能损伤和消化道反应均高于GG+GA型(P<0.05),儿童患者AA型骨髓抑制高于GG+GA型(P<0.05)。结论 RFC1 G80A基因多态性与大剂量甲氨蝶呤药物不良反应存在相关性,但仍需要更多大样本的临床研究来进行验证。
Objective To investigate the relationship between the polymorphism of RFC1 G80A gene and the adverse reactions of high dose methotrexate chemotherapy in Chinese population. Methods The association between RFC1 G80A gene polymorphism and high dose methotrexate adverse drug reactions was studied in Chinese population. Data were extracted from the clinical trials that met the criteria. Stata12.0 statistical software was used to analyze Meta-analysis. The differences of RFC1 G80A gene (AA vs GG + GA) in patients with adverse drug reactions. Results A total of 8 articles were included. Meta-analysis showed that: the Chinese population RFC1 G80A AA liver injury, renal damage and digestive tract reactions were higher than the GG + GA type (P <0.05), children with AA bone marrow suppression was higher than the GG GA type (P <0.05 ). Conclusions RFC1 G80A gene polymorphism is associated with high dose methotrexate adverse reactions, but more large clinical trials are still needed to verify the results.